Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wright Medical Group, a orthopedic device company, has launched Biotape XM Reinforcement Matrix, a sterile, acellular xenograft matrix for reinforcement of soft-tissue repairs in foot and ankle surgical procedures.
Subscribe to our email newsletter
According to Wright Medical, Biotape XM reinforcement matrix is the latest addition to the company’s biologics portfolio of technologies for foot and ankle surgery featuring Graftjacket regenerative tissue matrix, Prodense injectable regenerative graft, Cancello-Pure xenograft bone wedges, the Allomatrix family of demineralized bone matrix products, and Osteoset T medicated bone graft (not currently available in the US).
The company said that human biomechanical tests and animal studies with Biotape XM matrix revealed encouraging data for patients in need of surgical repair of injured tendons. When used to reinforce the repair of a tendon, Biotape XM matrix increases the strength of the initial repair by 70% on average when compared to suture repair alone.
In addition, animal studies support that the implant is well-tolerated by the host allowing fibroblast repopulation, revascularization and bio-integration with host tissue.
Wright will begin distribution of Biotape XM matrix in both the US and select international markets immediately through its worldwide extremity product sales force.
Eric Gay, Wright’s director of biologics marketing, said: “The launch of Biotape XM reinforcement matrix will help to expand our leadership position in the foot and ankle soft-tissue reinforcement market.
“In addition, Biotape XM Matrix, being a material of animal origin, will provide a less burdensome entrance into many of our international markets where human tissue regulations make providing human tissue products difficult and in some cases impossible.”